Table 1.
Characteristics of the 3 ADCs approved to date by the US Food and Drug Administration
| ADC name | Antibody target | Key IP right US/EP | Target also used in conventional mAb therapy? | Linker | Linker cleavable? | Toxin | Site specific conjugation? | Drug Antibody Ratio |
|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin** | CD33 | US5773001/ EP0689845B1* | no | hydrazone | yes | calicheamicin | no | Only 50% of the antibody is loaded at all (avg 4 – 6) |
| Trastuzumab emtansine | HER-2/neu | US8337856/ EP2283867B1 | yes | SMCC (maleimide) | no | DM1 (maytansinoid) | no | 0–8 (avg 3,5) |
| Brentuximab vedotin | CD30 | US7829531/ EP2353611B1 | no | maleimidocaproyl spacer, valine–citrulline linker, and PABC spacer | yes(cathepsin) | MMAE (auristatin) | no | 3–5 |
*
expired;
**
product voluntarily withdrawn from the market in 2010.